These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37272079)

  • 21. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy.
    Baune BT
    Curr Med Res Opin; 2024 Jan; 40(1):87-96. PubMed ID: 37999650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison.
    Harlin M; Chepke C; Larsen F; Bell Lynum KS; Chumki SR; Fitzgerald H; Such P; Madera-McDonough J; Yildirim M; Panni M; Saklad SR
    Neuropsychiatr Dis Treat; 2023; 19():1409-1416. PubMed ID: 37313228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.
    Mazza M; Squillacioti MR; Pecora RD; Janiri L; Bria P
    Expert Opin Pharmacother; 2008 Dec; 9(18):3145-9. PubMed ID: 19040335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies.
    Vieta E; Mullen J; Brecher M; Paulsson B; Jones M
    Curr Med Res Opin; 2005 Jun; 21(6):923-34. PubMed ID: 15969892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
    Kanba S; Murasaki M; Koyama T; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
    BMC Psychiatry; 2019 Jun; 19(1):198. PubMed ID: 31242884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
    McElroy SL; Suppes T; Frye MA; Altshuler LL; Stanford K; Martens B; Leverich GS; Post RM; Keck PE
    J Affect Disord; 2007 Aug; 101(1-3):275-81. PubMed ID: 17229469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.
    Juruena MF; Ottoni GL; Machado-Vieira R; Carneiro RM; Weingarthner N; Marquardt AR; Fleig SS; Broilo L; Busnello EA
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):94-9. PubMed ID: 19007842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
    Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.
    Perlis RH; Baker RW; Zarate CA; Brown EB; Schuh LM; Jamal HH; Tohen M
    J Clin Psychiatry; 2006 Nov; 67(11):1747-53. PubMed ID: 17196055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
    Keck PE; Calabrese JR; McIntyre RS; McQuade RD; Carson WH; Eudicone JM; Carlson BX; Marcus RN; Sanchez R;
    J Clin Psychiatry; 2007 Oct; 68(10):1480-91. PubMed ID: 17960961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.
    Ishigooka J; Nakamura J; Fujii Y; Iwata N; Kishimoto T; Iyo M; Uchimura N; Nishimura R; Shimizu N;
    Schizophr Res; 2015 Feb; 161(2-3):421-8. PubMed ID: 25556976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.
    Schöttle D; Janetzky W; Luedecke D; Beck E; Correll CU; Wiedemann K
    BMC Psychiatry; 2018 Nov; 18(1):365. PubMed ID: 30428862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
    Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
    Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.
    Chwieduk CM; Scott LJ
    CNS Drugs; 2011 Mar; 25(3):251-67. PubMed ID: 21323396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.
    Tohen M; McDonnell DP; Case M; Kanba S; Ha K; Fang YR; Katagiri H; Gomez JC
    Br J Psychiatry; 2012 Nov; 201(5):376-82. PubMed ID: 22918966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
    Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
    J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.
    Calabrese JR; Durgam S; Satlin A; Vanover KE; Davis RE; Chen R; Kozauer SG; Mates S; Sachs GS
    Am J Psychiatry; 2021 Dec; 178(12):1098-1106. PubMed ID: 34551584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
    CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.